<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39232046</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>04</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>04</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>The compartment-specific manipulation of the NAD<sup>+</sup>/NADH ratio affects the metabolome and the function of glioblastoma.</ArticleTitle><Pagination><StartPage>20575</StartPage><MedlinePgn>20575</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">20575</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-71462-8</ELocationID><Abstract><AbstractText>Glioblastoma multiforme (GBM) is the most aggressive type of cancer in the brain and has an inferior prognosis because of the lack of suitable medicine, largely due to its tremendous invasion. GBM has selfish metabolic pathways to promote migration, invasion, and proliferation compared to normal cells. Among various metabolic pathways, NAD (nicotinamide adenine dinucleotide) is essential in generating ATP and is used as a resource for cancer cells. LbNOX (Lactobacillus brevis NADH oxidase) is an enzyme that can directly manipulate the NAD<sup>+</sup>/NADH ratio. In this study, we found that an increased NAD<sup>+</sup>/NADH ratio by LbNOX or mitoLbNOX reduced intracellular glutamate and calcium responses and reduced invasion capacity in GBM. However, the invasion was not affected in GBM by rotenone, an ETC (Electron Transport Chain) complex I inhibitor, or nicotinamide riboside, a NAD<sup>+</sup> precursor, suggesting that the crucial factor is the NAD<sup>+</sup>/NADH ratio rather than the absolute quantity of ATP or NAD<sup>+</sup> for the invasion of GBM. To develop a more accurate and effective GBM treatment, our findings highlight the importance of developing a new medicine that targets the regulation of the NAD<sup>+</sup>/NADH ratio, given the current lack of effective treatment options for this brain cancer.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Lee</LastName><ForeName>Myunghoon</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, Chungnam National University, Daejeon, 34134, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Yoo</LastName><ForeName>Jae Hong</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, Chungnam National University, Daejeon, 34134, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Inseo</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>School of Pharmacy, Sungkyunkwan University, Suwon, 16419, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Sinbeom</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Molecular Biology, Chungnam National University, Daejeon, 34134, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Wonsik</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>School of Pharmacy, Sungkyunkwan University, Suwon, 16419, Republic of Korea. wonsik.lee@skku.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Sungjin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Molecular Biology, Chungnam National University, Daejeon, 34134, Republic of Korea. sungjin.kim@cnu.ac.kr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Kyung-Seok</ForeName><Initials>KS</Initials><Identifier Source="ORCID">0000-0003-2491-3069</Identifier><AffiliationInfo><Affiliation>Department of Biological Sciences, Chungnam National University, Daejeon, 34134, Republic of Korea. kshan711@cnu.ac.kr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2023-0097-02</GrantID><Agency>Ministry of Food and Drug Safety</Agency><Country /></Grant><Grant><GrantID>2023-0097-02</GrantID><Agency>Ministry of Food and Drug Safety</Agency><Country /></Grant><Grant><GrantID>2023-0097-02</GrantID><Agency>Ministry of Food and Drug Safety</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0U46U6E8UK</RegistryNumber><NameOfSubstance UI="D009243">NAD</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.6.-</RegistryNumber><NameOfSubstance UI="C023107">NADH oxidase</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009097">Multienzyme Complexes</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical><Chemical><RegistryNumber>3KX376GY7L</RegistryNumber><NameOfSubstance UI="D018698">Glutamic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>8L70Q75FXE</RegistryNumber><NameOfSubstance UI="D000255">Adenosine Triphosphate</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.6.-</RegistryNumber><NameOfSubstance UI="D009247">NADH, NADPH Oxidoreductases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005909" MajorTopicYN="Y">Glioblastoma</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009243" MajorTopicYN="Y">NAD</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055442" MajorTopicYN="Y">Metabolome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001932" MajorTopicYN="N">Brain Neoplasms</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009097" MajorTopicYN="N">Multienzyme Complexes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D052196" MajorTopicYN="N">Levilactobacillus brevis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009361" MajorTopicYN="N">Neoplasm Invasiveness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018698" MajorTopicYN="N">Glutamic Acid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000255" MajorTopicYN="N">Adenosine Triphosphate</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009247" MajorTopicYN="N">NADH, NADPH Oxidoreductases</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">LbNOX</Keyword><Keyword MajorTopicYN="N">Glioblastoma</Keyword><Keyword MajorTopicYN="N">Glutamate</Keyword><Keyword MajorTopicYN="N">Invasion</Keyword><Keyword MajorTopicYN="N">NAD+/NADH</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>5</Day><Hour>0</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>5</Day><Hour>0</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>4</Day><Hour>23</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39232046</ArticleId><ArticleId IdType="pmc">PMC11375122</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-71462-8</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-71462-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Louis, D. N. et al. The 2021 WHO classification of tumors of the central nervous system: A summary. Neuro-oncology23, 1231–1251 (2021). 10.1093/neuonc/noab106</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/neuonc/noab106</ArticleId><ArticleId IdType="pmc">PMC8328013</ArticleId><ArticleId IdType="pubmed">34185076</ArticleId></ArticleIdList></Reference><Reference><Citation>Bleeker, F. E., Molenaar, R. J. &amp; Leenstra, S. Recent advances in the molecular understanding of glioblastoma. J. Neuro-oncology108, 11–27 (2012).10.1007/s11060-011-0793-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11060-011-0793-0</ArticleId><ArticleId IdType="pmc">PMC3337398</ArticleId><ArticleId IdType="pubmed">22270850</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan, A. C. et al. Management of glioblastoma: State of the art and future directions. CA Cancer J. Clin.70, 299–312 (2020). 10.3322/caac.21613</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21613</ArticleId><ArticleId IdType="pubmed">32478924</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran, B. &amp; Rosenthal, M. Survival comparison between glioblastoma multiforme and other incurable cancers. J. Clin. Neurosci.17, 417–421 (2010). 10.1016/j.jocn.2009.09.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jocn.2009.09.004</ArticleId><ArticleId IdType="pubmed">20167494</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang, S. S. et al. Caffeine-mediated inhibition of calcium release channel inositol 1, 4, 5-trisphosphate receptor subtype 3 blocks glioblastoma invasion and extends survival. Cancer Res.70, 1173–1183 (2010). 10.1158/0008-5472.CAN-09-2886</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-09-2886</ArticleId><ArticleId IdType="pmc">PMC3273964</ArticleId><ArticleId IdType="pubmed">20103623</ArticleId></ArticleIdList></Reference><Reference><Citation>So, J. S., Kim, H. &amp; Han, K. S. Mechanisms of invasion in glioblastoma: Extracellular matrix, Ca(2+) signaling, and glutamate. Front. Cell Neurosci.15, 663092. 10.3389/fncel.2021.663092 (2021). 10.3389/fncel.2021.663092</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2021.663092</ArticleId><ArticleId IdType="pmc">PMC8206529</ArticleId><ArticleId IdType="pubmed">34149360</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinberg, R. A. The biology of cancer. (Garland science, 2013).</Citation></Reference><Reference><Citation>Stetler-Stevenson, W. G., Aznavoorian, S. &amp; Liotta, L. A. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Ann. Rev. Cell Biol.9, 541–573 (1993). 10.1146/annurev.cb.09.110193.002545</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.cb.09.110193.002545</ArticleId><ArticleId IdType="pubmed">8280471</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin, T. A., Ye, L., Sanders, A. J., Lane, J. &amp; Jiang, W. G. In Madame Curie Bioscience Database [Internet] (Landes Bioscience, 2013).</Citation></Reference><Reference><Citation>Mischel, P. S. et al. Identification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene22, 2361–2373 (2003). 10.1038/sj.onc.1206344</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.onc.1206344</ArticleId><ArticleId IdType="pubmed">12700671</ArticleId></ArticleIdList></Reference><Reference><Citation>de Groot, J. &amp; Sontheimer, H. Glutamate and the biology of gliomas. Glia59, 1181–1189 (2011). 10.1002/glia.21113</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.21113</ArticleId><ArticleId IdType="pmc">PMC3107875</ArticleId><ArticleId IdType="pubmed">21192095</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeuchi, S. et al. Increased xCT expression correlates with tumor invasion and outcome in patients with glioblastomas. Neurosurgery72, 33–41 (2013). 10.1227/NEU.0b013e318276b2de</Citation><ArticleIdList><ArticleId IdType="doi">10.1227/NEU.0b013e318276b2de</ArticleId><ArticleId IdType="pubmed">23096413</ArticleId></ArticleIdList></Reference><Reference><Citation>Radin, D. P. &amp; Tsirka, S. E. Interactions between tumor cells, neurons, and microglia in the glioma microenvironment. Int. J. Mol. Sci.21, 8476 (2020). 10.3390/ijms21228476</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21228476</ArticleId><ArticleId IdType="pmc">PMC7698134</ArticleId><ArticleId IdType="pubmed">33187183</ArticleId></ArticleIdList></Reference><Reference><Citation>Corsi, L., Mescola, A. &amp; Alessandrini, A. Glutamate receptors and glioblastoma multiforme: An old “Route” for new perspectives. Int. J. Mol. Sci.20, 1796 (2019). 10.3390/ijms20071796</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20071796</ArticleId><ArticleId IdType="pmc">PMC6479730</ArticleId><ArticleId IdType="pubmed">30978987</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyons, S. A., Chung, W. J., Weaver, A. K., Ogunrinu, T. &amp; Sontheimer, H. Autocrine glutamate signaling promotes glioma cell invasion. Cancer Res.67, 9463–9471. 10.1158/0008-5472.CAN-07-2034 (2007). 10.1158/0008-5472.CAN-07-2034</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-07-2034</ArticleId><ArticleId IdType="pmc">PMC2045073</ArticleId><ArticleId IdType="pubmed">17909056</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavlova, N. N. &amp; Thompson, C. B. The emerging hallmarks of cancer metabolism. Cell Metab.23, 27–47. 10.1016/j.cmet.2015.12.006 (2016). 10.1016/j.cmet.2015.12.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2015.12.006</ArticleId><ArticleId IdType="pmc">PMC4715268</ArticleId><ArticleId IdType="pubmed">26771115</ArticleId></ArticleIdList></Reference><Reference><Citation>Vander Heiden, M. G. Targeting cancer metabolism: A therapeutic window opens. Nat. Rev. Drug Discov.10, 671–684. 10.1038/nrd3504 (2011). 10.1038/nrd3504</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd3504</ArticleId><ArticleId IdType="pubmed">21878982</ArticleId></ArticleIdList></Reference><Reference><Citation>Agnihotri, S. &amp; Zadeh, G. Metabolic reprogramming in glioblastoma: the influence of cancer metabolism on epigenetics and unanswered questions. Neuro Oncol.18, 160–172. 10.1093/neuonc/nov125 (2016). 10.1093/neuonc/nov125</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/neuonc/nov125</ArticleId><ArticleId IdType="pmc">PMC4724176</ArticleId><ArticleId IdType="pubmed">26180081</ArticleId></ArticleIdList></Reference><Reference><Citation>Poteet, E. et al. Reversing the Warburg effect as a treatment for glioblastoma. J. Biol. Chem.288, 9153–9164. 10.1074/jbc.M112.440354 (2013). 10.1074/jbc.M112.440354</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.440354</ArticleId><ArticleId IdType="pmc">PMC3610988</ArticleId><ArticleId IdType="pubmed">23408428</ArticleId></ArticleIdList></Reference><Reference><Citation>Warburg, O. Origin of cancer cells. Oncologia9, 75–83 (1956). 10.1159/000223920</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000223920</ArticleId><ArticleId IdType="pubmed">13335077</ArticleId></ArticleIdList></Reference><Reference><Citation>Imai, S. &amp; Yoshino, J. The importance of NAMPT/NAD/SIRT1 in the systemic regulation of metabolism and ageing. Diabet. Obes. Metab.15(Suppl 3), 26–33. 10.1111/dom.12171 (2013).10.1111/dom.12171</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.12171</ArticleId><ArticleId IdType="pmc">PMC3819727</ArticleId><ArticleId IdType="pubmed">24003918</ArticleId></ArticleIdList></Reference><Reference><Citation>Mouchiroud, L. et al. The NAD(+)/Sirtuin pathway modulates longevity through activation of mitochondrial UPR and FOXO signaling. Cell154, 430–441. 10.1016/j.cell.2013.06.016 (2013). 10.1016/j.cell.2013.06.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2013.06.016</ArticleId><ArticleId IdType="pmc">PMC3753670</ArticleId><ArticleId IdType="pubmed">23870130</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy, B. E. et al. NAD(+) salvage pathway in cancer metabolism and therapy. Pharmacol. Res.114, 274–283. 10.1016/j.phrs.2016.10.027 (2016). 10.1016/j.phrs.2016.10.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2016.10.027</ArticleId><ArticleId IdType="pubmed">27816507</ArticleId></ArticleIdList></Reference><Reference><Citation>Hershberger, K. A., Martin, A. S. &amp; Hirschey, M. D. Role of NAD(+) and mitochondrial sirtuins in cardiac and renal diseases. Nat. Rev. Nephrol.13, 213–225. 10.1038/nrneph.2017.5 (2017). 10.1038/nrneph.2017.5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneph.2017.5</ArticleId><ArticleId IdType="pmc">PMC5508210</ArticleId><ArticleId IdType="pubmed">28163307</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodman, R. P. et al. Hepatic NADH reductive stress underlies common variation in metabolic traits. Nature583, 122–126. 10.1038/s41586-020-2337-2 (2020). 10.1038/s41586-020-2337-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2337-2</ArticleId><ArticleId IdType="pmc">PMC7536642</ArticleId><ArticleId IdType="pubmed">32461692</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu, Q. et al. Genetically encoded biosensors for evaluating NAD(+)/NADH ratio in cytosolic and mitochondrial compartments. Cell Rep. Methods10.1016/j.crmeth.2021.100116 (2021). 10.1016/j.crmeth.2021.100116</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.crmeth.2021.100116</ArticleId><ArticleId IdType="pmc">PMC8659198</ArticleId><ArticleId IdType="pubmed">34901920</ArticleId></ArticleIdList></Reference><Reference><Citation>Navas, L. E. &amp; Carnero, A. NAD+ metabolism, stemness, the immune response, and cancer. Signal Transduct. Target. Therapy6, 2 (2021).10.1038/s41392-020-00354-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-020-00354-w</ArticleId><ArticleId IdType="pmc">PMC7775471</ArticleId><ArticleId IdType="pubmed">33384409</ArticleId></ArticleIdList></Reference><Reference><Citation>Chowdhry, S. et al. NAD metabolic dependency in cancer is shaped by gene amplification and enhancer remodelling. Nature569, 570–575 (2019). 10.1038/s41586-019-1150-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1150-2</ArticleId><ArticleId IdType="pmc">PMC7138021</ArticleId><ArticleId IdType="pubmed">31019297</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, M. et al. Local targeting of NAD(+) salvage pathway alters the immune tumor microenvironment and enhances checkpoint immunotherapy in glioblastoma. Cancer Res.80, 5024–5034. 10.1158/0008-5472.CAN-20-1094 (2020). 10.1158/0008-5472.CAN-20-1094</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-20-1094</ArticleId><ArticleId IdType="pmc">PMC7669613</ArticleId><ArticleId IdType="pubmed">32998997</ArticleId></ArticleIdList></Reference><Reference><Citation>van Horssen, R. et al. Intracellular NAD (H) levels control motility and invasion of glioma cells. Cellul. Mol. Life Sci.70, 2175–2190 (2013).10.1007/s00018-012-1249-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-012-1249-1</ArticleId><ArticleId IdType="pmc">PMC11113314</ArticleId><ArticleId IdType="pubmed">23307072</ArticleId></ArticleIdList></Reference><Reference><Citation>da Veiga Moreira, J. et al. The redox status of cancer cells supports mechanisms behind the Warburg effect. Metabolites6, 33 (2016). 10.3390/metabo6040033</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/metabo6040033</ArticleId><ArticleId IdType="pmc">PMC5192439</ArticleId><ArticleId IdType="pubmed">27706102</ArticleId></ArticleIdList></Reference><Reference><Citation>Choe, M. &amp; Titov, D. V. Genetically encoded tools for measuring and manipulating metabolism. Nat. Chem. Biol.18, 451–460. 10.1038/s41589-022-01012-8 (2022). 10.1038/s41589-022-01012-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41589-022-01012-8</ArticleId><ArticleId IdType="pmc">PMC9093021</ArticleId><ArticleId IdType="pubmed">35484256</ArticleId></ArticleIdList></Reference><Reference><Citation>Geueke, B., Riebel, B. &amp; Hummel, W. NADH oxidase from Lactobacillus brevis: A new catalyst for the regeneration of NAD. Enzyme Microb. Technol.32, 205–211 (2003).10.1016/S0141-0229(02)00290-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0141-0229(02)00290-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Titov, D. V. et al. Complementation of mitochondrial electron transport chain by manipulation of the NAD+/NADH ratio. Science352, 231–235. 10.1126/science.aad4017 (2016). 10.1126/science.aad4017</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aad4017</ArticleId><ArticleId IdType="pmc">PMC4850741</ArticleId><ArticleId IdType="pubmed">27124460</ArticleId></ArticleIdList></Reference><Reference><Citation>Ojha, R. et al. Regulation of reverse electron transfer at mitochondrial complex I by unconventional Notch action in cancer stem cells. Dev. Cell57, 260-276.e269 (2022). 10.1016/j.devcel.2021.12.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.devcel.2021.12.020</ArticleId><ArticleId IdType="pmc">PMC8852348</ArticleId><ArticleId IdType="pubmed">35077680</ArticleId></ArticleIdList></Reference><Reference><Citation>Marvin, J. S. et al. An optimized fluorescent probe for visualizing glutamate neurotransmission. Nat. Methods10, 162–170. 10.1038/nmeth.2333 (2013). 10.1038/nmeth.2333</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.2333</ArticleId><ArticleId IdType="pmc">PMC4469972</ArticleId><ArticleId IdType="pubmed">23314171</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollenberg, M. D., Saifeddine, M., Al-Ani, B. &amp; Kawabata, A. Proteinase-activated receptors: Structural requirements for activity, receptor cross-reactivity, and receptor selectivity of receptor-activating peptides. Can. J. Physiol. Pharmacol.75, 832–841 (1997). 10.1139/y97-110</Citation><ArticleIdList><ArticleId IdType="doi">10.1139/y97-110</ArticleId><ArticleId IdType="pubmed">9315351</ArticleId></ArticleIdList></Reference><Reference><Citation>Woo, D. H. et al. TREK-1 and Best1 channels mediate fast and slow glutamate release in astrocytes upon GPCR activation. Cell151, 25–40. 10.1016/j.cell.2012.09.005 (2012). 10.1016/j.cell.2012.09.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2012.09.005</ArticleId><ArticleId IdType="pubmed">23021213</ArticleId></ArticleIdList></Reference><Reference><Citation>Sontheimer, H. A role for glutamate in growth and invasion of primary brain tumors. J. Neurochem.105, 287–295. 10.1111/j.1471-4159.2008.05301.x (2008). 10.1111/j.1471-4159.2008.05301.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2008.05301.x</ArticleId><ArticleId IdType="pmc">PMC2557065</ArticleId><ArticleId IdType="pubmed">18284616</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorensen, S. D. et al. Common signaling pathways link activation of murine PAR-1, LPA, and S1P receptors to proliferation of astrocytes. Mol. Pharmacol.64, 1199–1209. 10.1124/mol.64.5.1199 (2003). 10.1124/mol.64.5.1199</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/mol.64.5.1199</ArticleId><ArticleId IdType="pubmed">14573770</ArticleId></ArticleIdList></Reference><Reference><Citation>Roe, M. W., Lemasters, J. J. &amp; Herman, B. Assessment of Fura-2 for measurements of cytosolic free calcium. Cell Calcium11, 63–73. 10.1016/0143-4160(90)90060-8 (1990). 10.1016/0143-4160(90)90060-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0143-4160(90)90060-8</ArticleId><ArticleId IdType="pubmed">2191782</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, N. et al. Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production. J. Biol. Chem.278, 8516–8525. 10.1074/jbc.M210432200 (2003). 10.1074/jbc.M210432200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M210432200</ArticleId><ArticleId IdType="pubmed">12496265</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinz, S. et al. Mechanistic investigations of the mitochondrial complex I inhibitor rotenone in the context of pharmacological and safety evaluation. Sci. Rep.7, 45465. 10.1038/srep45465 (2017). 10.1038/srep45465</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep45465</ArticleId><ArticleId IdType="pmc">PMC5379642</ArticleId><ArticleId IdType="pubmed">28374803</ArticleId></ArticleIdList></Reference><Reference><Citation>Bogan, K. L. &amp; Brenner, C. Nicotinic acid, nicotinamide, and nicotinamide riboside: A molecular evaluation of NAD+ precursor vitamins in human nutrition. Annu. Rev. Nutr.28, 115–130. 10.1146/annurev.nutr.28.061807.155443 (2008). 10.1146/annurev.nutr.28.061807.155443</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.nutr.28.061807.155443</ArticleId><ArticleId IdType="pubmed">18429699</ArticleId></ArticleIdList></Reference><Reference><Citation>Alberghina, L. &amp; Gaglio, D. Redox control of glutamine utilization in cancer. Cell Death Dis.5, e1561–e1561 (2014). 10.1038/cddis.2014.513</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2014.513</ArticleId><ArticleId IdType="pmc">PMC4454159</ArticleId><ArticleId IdType="pubmed">25476909</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie, N. et al. NAD(+) metabolism: Pathophysiologic mechanisms and therapeutic potential. Signal Transduct. Target Ther.5, 227. 10.1038/s41392-020-00311-7 (2020). 10.1038/s41392-020-00311-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-020-00311-7</ArticleId><ArticleId IdType="pmc">PMC7539288</ArticleId><ArticleId IdType="pubmed">33028824</ArticleId></ArticleIdList></Reference><Reference><Citation>Yelamanchi, S. D. et al. A pathway map of glutamate metabolism. J. Cell Commun. Signal10, 69–75. 10.1007/s12079-015-0315-5 (2016). 10.1007/s12079-015-0315-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12079-015-0315-5</ArticleId><ArticleId IdType="pmc">PMC4850134</ArticleId><ArticleId IdType="pubmed">26635200</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin, J., Byun, J. K., Choi, Y. K. &amp; Park, K. G. Targeting glutamine metabolism as a therapeutic strategy for cancer. Exp. Mol. Med.55, 706–715. 10.1038/s12276-023-00971-9 (2023). 10.1038/s12276-023-00971-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s12276-023-00971-9</ArticleId><ArticleId IdType="pmc">PMC10167356</ArticleId><ArticleId IdType="pubmed">37009798</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim, M. J. et al. PPARdelta reprograms glutamine metabolism in sorafenib-resistant HCC. Mol. Cancer Res.15, 1230–1242. 10.1158/1541-7786.MCR-17-0061 (2017). 10.1158/1541-7786.MCR-17-0061</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1541-7786.MCR-17-0061</ArticleId><ArticleId IdType="pubmed">28584024</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao, J. et al. Mitochondrial dynamics regulates migration and invasion of breast cancer cells. Oncogene32, 4814–4824. 10.1038/onc.2012.494 (2013). 10.1038/onc.2012.494</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/onc.2012.494</ArticleId><ArticleId IdType="pmc">PMC3911914</ArticleId><ArticleId IdType="pubmed">23128392</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, H. &amp; Chan, D. C. Mitochondrial dynamics in regulating the unique phenotypes of cancer and stem cells. Cell Metab.26, 39–48. 10.1016/j.cmet.2017.05.016 (2017). 10.1016/j.cmet.2017.05.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2017.05.016</ArticleId><ArticleId IdType="pmc">PMC5539982</ArticleId><ArticleId IdType="pubmed">28648983</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu, D., Liu, C. &amp; Guo, L. Mitochondrial metabolism and cancer metastasis. Ann. Transl. Med.8, 904. 10.21037/atm.2020.03.42 (2020). 10.21037/atm.2020.03.42</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/atm.2020.03.42</ArticleId><ArticleId IdType="pmc">PMC7396750</ArticleId><ArticleId IdType="pubmed">32793748</ArticleId></ArticleIdList></Reference><Reference><Citation>Goetze, K., Walenta, S., Ksiazkiewicz, M., Kunz-Schughart, L. A. &amp; Mueller-Klieser, W. Lactate enhances motility of tumor cells and inhibits monocyte migration and cytokine release. Int. J. Oncol.39, 453–463. 10.3892/ijo.2011.1055 (2011). 10.3892/ijo.2011.1055</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ijo.2011.1055</ArticleId><ArticleId IdType="pubmed">21617859</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizwan, A. et al. Relationships between LDH-A, lactate, and metastases in 4T1 breast tumors. Clin. Cancer Res.19, 5158–5169. 10.1158/1078-0432.CCR-12-3300 (2013). 10.1158/1078-0432.CCR-12-3300</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-12-3300</ArticleId><ArticleId IdType="pmc">PMC3877680</ArticleId><ArticleId IdType="pubmed">23833310</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumann, F. et al. Lactate promotes glioma migration by TGF-beta2-dependent regulation of matrix metalloproteinase-2. Neuro Oncol.11, 368–380. 10.1215/15228517-2008-106 (2009). 10.1215/15228517-2008-106</Citation><ArticleIdList><ArticleId IdType="doi">10.1215/15228517-2008-106</ArticleId><ArticleId IdType="pmc">PMC2743217</ArticleId><ArticleId IdType="pubmed">19033423</ArticleId></ArticleIdList></Reference><Reference><Citation>Drent, M., Cobben, N. A., Henderson, R. F., Wouters, E. F. &amp; van Dieijen-Visser, M. Usefulness of lactate dehydrogenase and its isoenzymes as indicators of lung damage or inflammation. Eur. Respir. J.9, 1736–1742. 10.1183/09031936.96.09081736 (1996). 10.1183/09031936.96.09081736</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/09031936.96.09081736</ArticleId><ArticleId IdType="pubmed">8866602</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie, N. et al. NAD+ metabolism: Pathophysiologic mechanisms and therapeutic potential. Signal Transd. Target. Ther.5, 227 (2020).10.1038/s41392-020-00311-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-020-00311-7</ArticleId><ArticleId IdType="pmc">PMC7539288</ArticleId><ArticleId IdType="pubmed">33028824</ArticleId></ArticleIdList></Reference><Reference><Citation>Roos, J., Zinngrebe, J. &amp; Fischer-Posovszky, P. Nicotinamide mononucleotide: A potential effective natural compound against insulin resistance. Signal Transd. Target. Ther.6, 310 (2021).10.1038/s41392-021-00723-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00723-z</ArticleId><ArticleId IdType="pmc">PMC8376945</ArticleId><ArticleId IdType="pubmed">34413285</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia, J. &amp; Wishart, D. S. Web-based inference of biological patterns, functions and pathways from metabolomic data using MetaboAnalyst. Nat. Protoc.6, 743–760 (2011). 10.1038/nprot.2011.319</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2011.319</ArticleId><ArticleId IdType="pubmed">21637195</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>